Omid Farokhzad

Omid Farokhzad

Chair & Chief Executive Officer

Omid Farokhzad

Chair & Chief Executive Officer

Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
Chairman of the Board
Catherine Friedman

Catherine Friedman

Retired Managing Director at Morgan Stanley

Catherine Friedman

Retired Managing Director at Morgan Stanley

Catherine Friedman held numerous executive positions during a 23-year investment banking career with Morgan Stanley, including Managing Director, Head of West Coast Healthcare, and Co-Head of the Biotechnology Practice. She currently serves as the Chair of the Board of Directors of GRAIL, and is a member of the boards of directors of Altaba (formerly Yahoo!), Radius Health, and Lyell Immunopharma. She additionally serves as a trustee of The Darden School Foundation at the University of Virginia. She holds a B.A. in Economics from Harvard University and an M.B.A. from The University of Virginia’s Darden School of Business.
Independent Director
David Hallal

David Hallal

Former Chief Executive Officer at Alexion Pharmaceuticals

David Hallal

Former Chief Executive Officer at Alexion Pharmaceuticals

David Hallal is CEO, Chairman and Co-Founder at ElevateBio, as well as CEO and Chairman at AlloVir, and ElevateBio company. He is also Chairman of the Board of Directors at the biotechnology companies iTeos Therapeutics and Scholar Rock. Prior to his roles at iTeos and Scholar Rock, David was Chief Executive Officer of Alexion Pharmaceuticals, which he first joined in 2006. In addition to his CEO role, David also served as Board member, Chief Operating Officer, Chief Commercial Officer and Head of Commercial Operations. Before joining Alexion, David served as Vice President of Sales for OSI Eyetech from 2004 to 2006. He served as Head of Sales at Biogen from 2002 to 2004, and before that, he was at a variety of leadership roles at Amgen from 1992 to 2002. David began his pharmaceutical career at The Upjohn Company, where he was a sales representative from 1998 to 1992. He has a B.A. in psychology from the University of New Hampshire.
Independent Director
Robert Langer, Sc.D.

Robert Langer, Sc.D.

Co-Chairman of Scientific Advisory Board

Robert Langer, Sc.D.

Co-Chairman of Scientific Advisory Board

Dr. Langer is the Chair of Seer’s Scientific Advisory Board. He is an Institute Professor at the Massachusetts Institute of Technology. Dr. Langer’s scientific work, particularly in drug delivery systems and tissue engineering, has been cited over 275,000 times with an H-Index of 262, and his inventions include over 1300 issued or pending patents. He is the youngest person ever elected to all three U.S. National Academies (Science, Engineering, and Medicine). He is one of 4 living individuals to have won both the U.S. National Medal of Science (2006) and the U.S. National Medal of Technology and Innovation (2011); and he has won over 220 other major awards. He served as a member of the U.S. FDA’s Science Board from 1995 — 2002 and as its Chairman from 1999-2002. Dr. Langer has co-founded over 26 companies, including Moderna, Momenta, and Transform. Dr. Langer has a bachelor’s degree in chemical engineering from Cornell University and an Sc.D. in chemical engineering from MIT.
Independent Director
Terry McGuire

Terry McGuire

Founding Partner of Polaris Partners

Terry McGuire

Founding Partner of Polaris Partners

Terry McGuire is Founding Partner of Polaris Partners. As a venture capitalist, he has invested in more than 50 companies, and has also co-founded three companies: Inspire Pharmaceuticals (public and sold to Merck), AIR (sold to Alkemes) and MicroCHIPS (private). Companies that Terry has supported have raised over $6 billion in equity and corporate capital. In 2013, Terry was listed as one of Forbes’ Top Life Sciences Investors, and in 2011, he was listed in Forbes’ Midas 100 List of Top Tech Investors. He currently chairs the Board of the Thayer School for Engineering, Dartmouth College, and serves on the Boards of the David Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS). Terry has a BS in physics and economics from Hobart College, an MS in engineering from The Thayer School at Dartmouth College, and an MBA from Harvard Business School.
Independent Director
Omead Ostadan

Omead Ostadan

President & Chief Operating Officer

Omead Ostadan

President & Chief Operating Officer

Omead Ostadan is the President and Chief Operating Officer for Seer, as well as a member of our Board of Directors. He was most recently Chief Product and Marketing Officer and a member of Illumina’s executive management team. He joined Illumina in 2007 as Vice President of Marketing and built the company’s marketing organization during a period of tremendous growth and diversification. In 2011 Mr. Ostadan was Senior Vice President of Product Development and in 2015 his role expanded to include the company’s Global Operations and Quality functions. Prior to joining Illumina, Mr. Ostadan was Vice President of Marketing at Solexa from 2005-2007. Before Solexa, Mr. Ostadan held a variety of marketing roles at Applied Biosystems over a nearly 10-year span, where he managed the company’s high throughput sequencing platforms. Mr. Ostadan holds a BS in Biochemistry from the University of California at Davis and an MBA from The Wharton School at the University of Pennsylvania.
David Singer

David Singer

Managing Partner at Maverick Ventures

David Singer

Managing Partner at Maverick Ventures

David Singer is Managing Partner of Maverick Capital Ventures, part of Maverick Capital Ltd., an investment fund with almost $11 billion under management. Prior to joining Maverick in 2004, David was a founder and executive for three health care companies – Affymetrix, where he served as President and Chief Executive; Corcept Therapeutics, where he served as its Chief Executive Officer; and GeneSoft Pharmaceuticals, where he served as Chairman. In addition to GeneSoft, David has also served on the Boards of Pacific Biosciences, Affymetrix, Corcept Therapeutics, and Oscient Pharmaceuticals. He currently serves on the Board of several private healthcare companies. David served as a health commissioner of San Francisco and a member of the San Francisco General Hospital Joint Conference Committee. He has a B.A. degree in history from Yale University and an M.B.A. from Stanford University.
Independent Director

Search Investor Relations